Financials Caliway Biopharmaceuticals Co., Ltd.

Equities

6919

TW0006919004

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
379 TWD -1.04% Intraday chart for Caliway Biopharmaceuticals Co., Ltd. -0.26% +98.17%

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 7,528 26,600
Enterprise Value (EV) 1 6,446 22,909
P/E ratio -25.1 x -48.5 x
Yield - -
Capitalization / Revenue 587 x 683 x
EV / Revenue 503 x 588 x
EV / EBITDA -21.3 x -46.4 x
EV / FCF -37,680,260 x -85,994,424 x
FCF Yield -0% -0%
Price to Book 6.48 x 7.12 x
Nbr of stocks (in thousands) 122,910 139,084
Reference price 2 61.25 191.2
Announcement Date 4/21/23 3/4/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 18.65 10.35 12.34 12.82 38.93
EBITDA 1 -106.7 -76.72 -161.4 -302.4 -493.7
EBIT 1 -122.1 -87.89 -177.6 -319.6 -513.5
Operating Margin -654.87% -849.16% -1,439.72% -2,493.17% -1,318.88%
Earnings before Tax (EBT) 1 -121.8 -98.4 -224.3 -286.2 -488.5
Net income 1 -121.8 -98.49 -224.3 -286.2 -488.5
Net margin -653.27% -951.56% -1,817.76% -2,232.1% -1,254.64%
EPS 2 -1.743 -0.9247 -1.707 -2.443 -3.943
Free Cash Flow - - -29.73 -171.1 -266.4
FCF margin - - -240.91% -1,334.34% -684.26%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 11/10/22 9/23/22 9/23/22 4/21/23 3/4/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 134 42.4 - - -
Net Cash position 1 - - 547 1,083 3,691
Leverage (Debt/EBITDA) -1.254 x -0.5527 x - - -
Free Cash Flow - - -29.7 -171 -266
ROE (net income / shareholders' equity) - - -64.9% -31.6% -19.9%
ROA (Net income/ Total Assets) - - -23.5% -20.5% -12.7%
Assets 1 - - 953.8 1,394 3,850
Book Value Per Share 2 -0.1300 0.4400 6.020 9.460 26.90
Cash Flow per Share 2 0.3100 0.8300 5.450 5.320 24.60
Capex - 2.31 14.9 14.2 8.6
Capex / Sales - 22.29% 120.79% 110.48% 22.09%
Announcement Date 11/10/22 9/23/22 9/23/22 4/21/23 3/4/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. 6919 Stock
  4. Financials Caliway Biopharmaceuticals Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW